Enfusion, Inc. (NYSE:ENFN) Holdings Raised by Wasatch Advisors LP

Wasatch Advisors LP grew its position in Enfusion, Inc. (NYSE:ENFN) by 34.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 792,083 shares of the company’s stock after acquiring an additional 201,771 shares during the quarter. Wasatch Advisors LP owned approximately 0.62% of Enfusion worth $7,327,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Algert Global LLC acquired a new position in Enfusion during the 3rd quarter valued at approximately $139,000. Hudson Bay Capital Management LP boosted its position in Enfusion by 29.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock valued at $4,127,000 after purchasing an additional 105,236 shares during the period. Vanguard Group Inc. boosted its position in Enfusion by 17.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock valued at $31,286,000 after purchasing an additional 512,479 shares during the period. Swiss National Bank boosted its position in Enfusion by 17.4% during the 4th quarter. Swiss National Bank now owns 58,100 shares of the company’s stock valued at $564,000 after purchasing an additional 8,600 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Enfusion by 680.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock valued at $96,000 after purchasing an additional 8,627 shares during the period. 81.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Enfusion

In other Enfusion news, insider Bronwen Bastone sold 18,241 shares of the business’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $8.11, for a total value of $147,934.51. Following the transaction, the insider now owns 198,913 shares in the company, valued at $1,613,184.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Bronwen Bastone sold 18,241 shares of the company’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $8.11, for a total transaction of $147,934.51. Following the completion of the sale, the insider now owns 198,913 shares in the company, valued at approximately $1,613,184.43. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Deirdre Somers sold 4,629 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $8.40, for a total value of $38,883.60. Following the sale, the director now owns 43,312 shares of the company’s stock, valued at approximately $363,820.80. The disclosure for this sale can be found here. Insiders have sold 36,318 shares of company stock worth $296,688 over the last 90 days. 36.44% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ENFN shares. Bank of America boosted their price target on Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 13th. Morgan Stanley started coverage on Enfusion in a research report on Friday, May 10th. They set an “overweight” rating and a $11.00 price target for the company. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Enfusion Stock Performance

NYSE:ENFN traded up $0.03 during trading hours on Tuesday, hitting $8.43. 151,760 shares of the company’s stock traded hands, compared to its average volume of 379,243. The firm has a market cap of $1.08 billion, a P/E ratio of 280.93, a P/E/G ratio of 1.98 and a beta of 0.92. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $11.56. The stock’s fifty day moving average price is $9.04 and its two-hundred day moving average price is $9.03.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The business had revenue of $48.05 million for the quarter, compared to analyst estimates of $47.67 million. During the same period in the previous year, the firm posted $0.04 earnings per share. On average, equities research analysts predict that Enfusion, Inc. will post 0.09 earnings per share for the current year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.